BioWorld

July 19, 2002

Orphan Medical Cataplexy Drug Xyrem Approved By FDA

Nearly two years after the company filed its new drug application, Orphan Medical Inc. said after the markets closed Wednesday it won FDA approval for Xyrem, designed to treat cataplexy associated with narcolepsy. (BioWorld Today) Read More

Senate Passes Reimportation Amendment; Vote Weeks Away

Brain's Fissured, Furrowed Gray Matter Replicated In Transgenic Mice To See Cortex Overgrowth

Focused On Drug Discovery, Scion Closes $17.5M Round

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...